Moderna’s Opportunistic Bid for BioNTech’s Shuttered German Plants Underscores a Stock Caught Between Restructuring and Pipeline Promise

BioNTech cuts nearly 2,000 jobs, closes three sites; Moderna eyes buying them. Despite oncology pipeline progress, stock remains depressed amid revenue plunge.

BioNTech is weathering a painful transition. The company that rode the pandemic vaccine boom to billions in revenue is now slashing nearly 2,000 jobs, closing three German sites, and pivoting to oncology — all while its most formidable rival circles the discarded factories like a vulture. Moderna confirmed on Wednesday that it is evaluating the purchase of BioNTech’s facilities in Idar-Oberstein, Marburg and Tübingen, sending BioNTech’s stock up nearly 4% to €80.25. The move adds a geopolitical twist to an already complex narrative: Moderna chief Stéphane Bancel warned that Europe faces a “massive sovereignty problem” as Chinese companies build at least five new mRNA specialists, and he made clear that any deal hinges on the German government improving the regulatory environment.

The offer could provide an elegant solution for BioNTech’s empty Tübingen plant, which the company is scheduled to vacate by the end of 2026. A regional task force has been scrambling since late May to find a tenant. But the factory fire sale is just one piece of a deeper upheaval. The company’s founders, Ugur Sahin and Özlem Türeci, are pushing ahead with a plan to spin off certain assets into a new entity controlled by them — a move that has drawn sharp criticism from minority shareholders. Bernd Förtsch, the publisher of Der Aktionär, is demanding an independent valuation and a special committee to ensure transparency. The timing could hardly be worse: revenue has plunged from more than €7 billion at the peak to a projected €2–2.3 billion this year, and the austerity programme will cost nearly 2,000 jobs.

Yet beneath the operational noise, BioNTech’s oncology pipeline is quietly generating data that many analysts argue the market is ignoring. At the recent ASCO conference, the company presented results for two key assets. Pumitamig showed anti-tumour activity in the ROSETTA-Lung-02 trial targeting first-line lung cancer. Gotistobart delivered durable survival benefits in platinum-resistant ovarian cancer. The stock, however, barely blinked. It continues to trade below both its 50-day moving average of €81.07 and its long-term average of roughly €85, and remains more than 26% below its 52-week high.

The valuation disconnect is stark. At a share price of €77.95 (prior to the Moderna-driven bounce), BioNTech’s market capitalisation stood at about €19.7 billion. Strip out the company’s enormous cash reserves, and the entire oncology pipeline is being priced at just a few billion euros — a fraction of what many analysts believe it is worth. The first quarter of 2026 did little to soothe bears: revenue came in at €118.1 million and the net loss widened to €531.9 million. Management reaffirmed its full-year guidance of €2.0–2.3 billion in sales, but spending on R&D and commercial infrastructure is climbing as the company prepares for its first oncology launches — none of which will generate revenue this year.

Still, the second half of 2026 is packed with potential catalysts. BioNTech plans to kick off six additional Phase 3 trials, bringing the total to 15. Several important readouts are expected, including data for Trastuzumab Pamirtecan in endometrial cancer and final results for Gotistobart in lung cancer. The company also aims to file for approval of Trastuzumab Pamirtecan before year-end. Meanwhile, the long-term objective is to save €500 million annually, with the freed capital channelled directly into the oncology transformation. Crucially, the first pivotal data for Pumitamig — the antibody-drug conjugate that is arguably the most important candidate in the pipeline — is not expected until 2027.

Analysts are already out in front of the market. UBS raised its rating to Buy shortly before ASCO, lifting its price target to $135. The average analyst target now sits at €106.71, implying roughly 37% upside from current levels. Remarkably, not a single analyst covering the stock recommends selling. That degree of consensus is unusual for a volatile biotech name, but it underscores the gap between near-term financial pain and long-term scientific promise.

The bull case boils down to patience. With 13 ongoing registration trials and a deep balance sheet, BioNTech has the firepower to absorb losses while the pipeline matures. The bear case, however, is equally real: delays in those trials would hit the stock hard, and the shrinking vaccine revenue will continue to weigh on sentiment. At a price just 14% above its 52-week low, the market is effectively pricing in failure. The ASCO data suggest that might be too pessimistic. If one of the late-stage lung cancer readouts delivers a positive outcome, the stock could break out of its rut — and the factories Moderna covets may become a footnote in a much bigger story.